Corcept (CORT) Q4 2025 Earnings Transcript

Corcept reported 2025 revenue of $761 million, up from $675 million, and guided 2026 revenue to $900 million-$1 billion, supported by strong Korlym demand and normalized specialty pharmacy operations. However, the FDA denied relacorilant for Cushing’s syndrome, offsetting positive ROSELLA Phase III ovarian cancer data showing a 35% reduction in death risk (HR 0.65) and a 4.1-month median overall survival gain. The company also ended 2025 with $532 million in cash and investments after repurchasing $245 million of stock, while ongoing litigation and regulatory uncertainty remain key risks.

Analysis

The market is underestimating how much of the revenue step-up is now self-help rather than pure market expansion. The specialty-pharmacy reset removes a distribution bottleneck that had capped conversion of demand into shipments; that means the next two quarters should show an unusually clean operating leverage inflection if new starts stay elevated. More importantly, the AG mix appears to have mostly stabilized, so the revenue quality issue is less about further channel erosion and more about whether the current run-rate can sustain mid-teens growth once transition noise fully rolls off.

The bigger strategic swing is regulatory optionality. The FDA setback on relacorilant in Cushing’s likely shifts the stock from a one-event approval story to a sequence-of-events story: April FDA meeting, potential resubmission/appeal, then a much larger wait if a new study is required. That compresses the near-term multiple on the endocrinology franchise, but it also raises the probability that investors will start valuing the oncology asset as a separate call option because ROSELLA is now the cleaner path to an inflection. If management can convert the upcoming SGO package into a credible commercial narrative, the oncology mix could start to matter earlier than consensus assumes, especially if launch timing lands inside 2H.

The contrarian angle is that the disappointment may be overstated relative to the underlying asset value. The company now has multiple shots on goal across three distinct disease areas, and the current setup resembles a platform with regulatory friction rather than a binary pipeline. The key risk is not just the FDA decision itself; it is whether investors extrapolate a longer development delay into a worse view of the entire GR-antagonist mechanism. That would be the wrong inference if upcoming data keep validating the biology in adjacent indications.

The cleanest bear case is execution risk, not science risk: one pharmacy hiccup, one regulatory reset, or one safety signal in a new indication can quickly slow the growth narrative. But if the next two data events — oncology deep-dive and MOMENTUM — are clean, the stock can re-rate on pipeline durability even before Cushing’s approval clarity returns.

Key Decisions for Investors

• Go long CORT on weakness into the April FDA meeting, with a 3-6 month horizon: upside is driven by a binary reduction in regulatory uncertainty and continued commercial acceleration; risk is a formal request for a new study that pushes the relacorilant Cushing’s value stream out by 12+ months.
• Add a tactical long CORT / short biotech basket pair (e.g., XBI) into the MOMENTUM and SGO readouts: the trade expresses company-specific catalyst asymmetry while hedging broad sector beta; stop if either catalyst disappoints on safety or efficacy.
• If you own CORT, hedge with short-dated puts into SGO or the FDA meeting window: implied volatility should remain elevated, and a downside surprise from regulatory ambiguity is the cleanest near-term de-risk event.
• For more risk-tolerant accounts, consider a call spread on CORT over 6-9 months: the structure captures a potential re-rating if oncology begins to contribute to perception, while limiting damage if the FDA path remains prolonged.
• Avoid chasing after a sharp rally until the market sees either finalized FDA next steps or a clean oncology slide deck; the stock likely needs a hard catalyst, not just narrative improvement, to de-risk the regulatory overhang.